Company Encyclopedia
View More
name
IN8bio
INAB.US
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; and INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer. The company was formerly known as Incysus Therapeutics, Inc.
1.946 T
INAB.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Shares of IN8bio are trading higher. The company announced consolidated data from its Phase 1 single-center clinical trial of INB-200 and Phase 2 multi-center trial of INB-400 for the treatment of patients with newly diagnosed glioblastoma at 2025 SNO Annual Meeting.

    benzinga_article·
    US
    INAB
    +4.00%
    benzinga_article·
    US
    INAB
    +4.00%

    IN8BIO Reports Promising Survival Data for DeltEx DRI Cells in Glioblastoma Trial

    IN8BIO Inc. announced promising results from its Phase 1 and Phase 2 trials of DeltEx DRI gamma-delta T cells for glioblastoma treatment. Presented at the 2025 SNO Annual Meeting, 17 patients treated with DeltEx DRI cells showed a median progression-free survival of 13.0 months, compared to 6.6 months with standard care. Median overall survival for repeated doses was 16.4+ months, surpassing the 11.0 months of standard care. The data was published via EDGAR by IN8BIO Inc.

    Reuters·
    US
    INAB
    +4.00%
    Reuters·
    US
    INAB
    +4.00%

    IN8BIO Showcases Advances in Gamma-Delta T Cell Therapies in New Corporate Presentation

    IN8BIO Inc. has released a corporate presentation detailing advancements in its gamma-delta T cell therapies. Updates include clinical milestones for acute myeloid leukemia and glioblastoma programs, with significant data expected in 2026. Autoimmune indications are on hold, with potential IND-enabling studies in 2026. Further details are available in SEC filings.

    Reuters·
    US
    INAB
    +4.00%
    Reuters·
    US
    INAB
    +4.00%

    In8bio Inc Files For Mixed Shelf Offering Of Upto $200 Million - SEC Filing

    IN8bio Inc :IN8BIO INC FILES FOR MIXED SHELF OFFERING OF UPTO $200 MILLION - SEC FILING

    Reuters·
    US
    INAB
    +4.00%
    Reuters·
    US
    INAB
    +4.00%

    IN8Bio Reports Improved Financials Amid Ongoing Challenges

    In8bio, Inc. (INAB) reported its Q3 earnings, showing a net loss of $3.85 million, an improvement from $7.09 million last year. The company, focused on gamma-delta T cell therapies, has reduced operating costs from $7.11 million to $3.97 million. Despite these improvements, there are concerns about its ability to continue operations without additional capital in the next 12 months. Management is committed to advancing clinical programs and exploring strategic collaborations for future growth.

    Tip Ranks·
    US
    INAB
    +4.00%
    Tip Ranks·
    US
    INAB
    +4.00%
    © 2025 Longbridge｜Disclaimer